RxDoctor Payments Data

Debra McCutcheon

Anesthesiology · Morehead City, NCNPI 1184804411

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (40.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Nevro Corp. at 59.8% of the total. Reporting peaked in 2019 at $18,720 and has fallen 90.8% since, to $1,719 in 2025. Among anesthesiology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,879in general payments, 2019–2025

Across 386 payments — averaging $103.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$24K
  • Boston Scientific$9K
  • Saluda Medical Americas, Inc.$3K
  • AbbVie$642
  • Spinal Simplicity, LLC$625
  • Abbott$360
  • plus $3K from 38 others

What the payments were for

  • Consulting fees$7,47519%
  • Speaking & faculty fees$16,10040%
  • Travel & lodging$5,49814%
  • Food & beverage$10,80527%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,879 in reported general payments places this provider in the 95th percentile of 1,149 anesthesiology providers in North Carolina.

See all anesthesiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$390,598
Medicare patients
440
Services billed
15,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina48$67,016
QuliptaAtogepant11$11,187
Buprenorphine23$5,643
OxycontinOxycodone Hcl14$4,103
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen62$2,808
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen69$1,637
Oxycodone Hcl55$1,263
Gabapentin88$1,071
Tramadol Hcl65$681
Pregabalin31$583
Hydromorphone Hcl15$376
Celecoxib14$355
Tizanidine Hcl31$337
Baclofen17$311
Diclofenac Sodium21$244

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Qulipta$642$78,20259 claims
Hikma Pharmaceuticals USABuprenorphine$12$5,64323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,149 anesthesiology providers in North Carolina.

Other anesthesiology in Morehead City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →